Projects per year
Personal profile
Research interests
Dr. Patricia McLaughlin’s research focuses on the Opioid Growth Factor (OGF) – OGF receptor (OGFr) pathway and mechanisms of action in homeostasis and disease. Early collaborative work with Dr. Ian Zagon resulted in the identification of [Met5]-enkephalin as the endogenous ligand for the OGF-OGFr pathway. Subsequently, a new nuclear-associated receptor was identified and termed OGFr. One group in the laboratory has characterized and cloned the OGFr gene in human, mouse and rat. Protein chemistry studies, along with structural biology, determined that the OGFr is a uniquely unstructured nuclear receptor. The mechanism of action was determined to involve inhibition of DNA synthesis with the specific mechanistic pathway involving upregulation of cyclin-dependent inhibitory kinases p16 and p21. OGF action is receptor-mediated, reversible, and not associated with apoptosis/necrosis. OGF is tissue non-specific and has been identified in proliferating cells and tissues derived from all 3 dermal layers.
Currently, the lab’s work is translational, focusing on disease-based pathways that are characterized by a perturbation in the OGF-OGFr axis. Consequences of receptor blockade of the OGF-OGFr axis are being studied with an emphasis on the etiology and treatment of complications (e.g., delayed wound healing, dry eye, impaired bone composition) arising from long-term diabetes (Type 1 or Type 2). These investigations (humans and animal models) focus on treatment options and utilize confocal microscopy, animal surgery, immunohistochemistry and tissue culture.
In another series of studies, the lab is testing the hypothesis that down-regulation of the inhibitory OGF peptide plays a role in multiple sclerosis and other autoimmune diseases. The lab is also currently validating serum biomarkers and cytokine expression profiles that correspond to changes in behavior and MRI imaging that may be related to disease progression and response to therapy. The clinical and animal research is both qualitative and quantitative in design and is supported by NIH, ADA, TSF (PA) and foundations.
Fingerprint Dive into the research topics where Patricia McLaughlin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 5 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
- 1 Finished
ENDOGENOUS OPIOID SYSTEMS AND HEART DEVELOPMENT
National Heart, Lung, and Blood Institute
1/1/94 → 12/31/95
Project: Research project
Research Output
Blockade of the OGF-OGFr pathway in diabetic bone
Titunick, M. B., Lewis, G. S., Cain, J. D., Zagon, I. S. & McLaughlin, P. J., Jan 1 2019, In : Connective Tissue Research. 60, 6, p. 521-529 9 p.Research output: Contribution to journal › Article
Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
McLaughlin, P. J., Sassani, J. W., Titunick, M. B. & Zagon, I. S., Jan 28 2019, In : BMC Ophthalmology. 19, 1, 35.Research output: Contribution to journal › Article
1
Scopus
citations
Featured Article: Modulation of the OGF–OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis
Ludwig, M. D., Zagon, I. S. & McLaughlin, P. J., Feb 1 2018, In : Experimental Biology and Medicine. 243, 4, p. 361-369 9 p.Research output: Contribution to journal › Article
3
Scopus
citations
Intermittent blockade of OGFr and treatment of autoimmune disorders
Zagon, I. S. & McLaughlin, P. J., Dec 1 2018, In : Experimental Biology and Medicine. 243, 17-18, p. 1323-1330 8 p.Research output: Contribution to journal › Review article
1
Scopus
citations
Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis
Ludwig, M. D., Zagon, I. S. & McLaughlin, P. J., Sep 2017, In : Brain Research Bulletin. 134, p. 1-9 9 p.Research output: Contribution to journal › Article
8
Scopus
citations